Non-Operating Income/Expense: The sum of all non-operating expenses for the given industry.
Rigel Pharmaceuticals, Inc. (RIGL) had Non-Operating Income/Expense of $-3.64M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$294.28M |
|
$367.02M |
|
$19.62M |
|
$274.66M |
|
$168.82M |
|
$125.47M |
|
|
Non-Operating Income/Expense |
$-3.64M |
$121.83M |
|
$121.83M |
|
$367.02M |
|
$367.02M |
|
$367.02M |
|
$367.02M |
|
$125.47M |
|
$126.73M |
|
17.99M |
|
18.84M |
|
$20.40 |
|
$19.48 |
|
| Balance Sheet Financials | |
$240.17M |
|
-- |
|
$273.43M |
|
$513.59M |
|
$99.24M |
|
$22.48M |
|
$22.88M |
|
$122.11M |
|
$391.48M |
|
$366.73M |
|
$391.48M |
|
18.31M |
|
| Cash Flow Statement Financials | |
$75.66M |
|
$-92.36M |
|
$0.60M |
|
$56.75M |
|
$40.64M |
|
$-16.11M |
|
$12.71M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.42 |
|
-- |
|
-- |
|
0.05 |
|
0.13 |
|
93.33% |
|
42.63% |
|
42.63% |
|
43.06% |
|
41.40% |
|
124.72% |
|
$75.66M |
|
-- |
|
-- |
|
-- |
|
0.57 |
|
1.71 |
|
5.69 |
|
64.20 |
|
93.75% |
|
100.08% |
|
71.46% |
|
88.66% |
|
$21.38 |
|
$4.02 |
|
$4.02 |
|